Cullgen

Cullgen, Inc. operates as a clinical-stage biopharmaceutical company, founded in 2018 by Dr. Jian Jin and Dr. Yue Xiong, with its headquarters in San Diego, USA, and operations in Shanghai, China. The founders possess extensive research backgrounds in the ubiquitin-proteasome system (UPS), with Dr. Xiong being credited as one of the first to discover key components of the cullin-RING family of E3 ubiquitin ligases in 1998. This deep expertise forms the scientific foundation of the company.

The company's business is centered on the discovery and development of small molecule therapeutics that utilize targeted protein degradation to treat diseases, with a primary focus on oncology, as well as inflammatory, autoimmune, and neurodegenerative diseases. Its core technology is a proprietary platform named uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination). This platform engineers small molecules that co-opt the body's natural UPS to selectively tag and eliminate disease-causing proteins, including those historically considered "undruggable" by traditional inhibitor drugs. Cullgen's business model involves building its own pipeline of drug candidates and entering into strategic partnerships with other pharmaceutical companies. A significant collaboration was established with Astellas Pharma in 2023 to discover and develop cell cycle protein degraders for breast cancer and other solid tumors, a deal potentially worth over $1.9 billion.

Cullgen is advancing a pipeline of targeted protein degraders and degrader-antibody conjugates (DACs). Its most advanced program, CG001419, is a first-in-class, oral pan-TRK degrader currently in Phase 1 clinical trials for two separate indications: solid tumors and pain management. The pain management trial, which began in early 2025, aims to provide a new non-opioid and non-NSAID analgesic. Another candidate, CG009301, is a GSPT1 degrader for blood cancers, with a clinical trial anticipated to start in the first quarter of 2025. The company has successfully raised significant capital to fund its operations, securing a total of $121 million over four rounds, including a $50 million Series B in 2021 and a $40 million Series C financing in 2023, led by major investors like AstraZeneca-CICC Venture Capital Partnership, Sequoia Capital, and GNI Group. In November 2024, Cullgen announced a proposed merger with Pulmatrix, Inc., which would result in it becoming a Nasdaq-listed company.

Keywords: targeted protein degradation, uSMITE, protein degrader, E3 ubiquitin ligase, small molecule therapeutics, oncology, undruggable targets, biopharmaceutical, clinical-stage, proteasome system, cancer therapy, ubiquitin, CG001419, pan-TRK degrader, GSPT1 degrader, degrader-antibody conjugates, DACs, autoimmune diseases, neurodegenerative diseases, Jian Jin, Yue Xiong, Astellas Pharma